HCPCS code J0775: Billing guide for collagenase clostridium histolyticum

Key Takeaways

HCPCS code J0775 describes the injection of collagenase clostridium histolyticum (Xiaflex) at 0.01 mg per billable unit

Each 0.01 mg equals one unit of service. A standard 0.58 mg Dupuytren’s dose equals 58 units, and a 0.9 mg Peyronie’s dose equals 90 units

Only two ICD-10-CM codes support J0775 claims: M72.0 (Dupuytren’s contracture) and N48.6 (Peyronie’s disease)

Prior authorization is required by most commercial payers. JW and JZ modifiers are mandatory when reporting drug waste or confirming no waste

HCPCS code J0775 is the billing code for injection of collagenase clostridium histolyticum, the enzyme therapy sold as Xiaflex for Dupuytren’s contracture and Peyronie’s disease. This reference covers everything coders, billers, and clinical staff need to submit clean J0775 claims, from unit calculations and the ICD-10 crosswalk to JW/JZ modifier requirements and prior authorization workflows.

The guide reflects 2026 CMS guidance and current commercial payer policies from UnitedHealthcare, Cigna, and Moda Health. Verify specific reimbursement rates for your MAC jurisdiction before submitting claims.

HCPCS code J0775: code description and drug properties

HCPCS code J0775 is maintained by CMS under the Drugs Administered Other Than Oral Method category (J0120-J7175). Its official descriptor is:

Injection, collagenase, clostridium histolyticum, 0.01 mg

Xiaflex is a biologic enzyme that breaks down the collagen-dense cords in Dupuytren’s contracture and the plaques of Peyronie’s disease.

Because it’s administered in the office or an ambulatory surgery center rather than a pharmacy, it follows the claims management buy-and-bill model. The practice purchases the drug directly and submits J0775 to recover the acquisition cost plus applicable add-on reimbursement from Medicare or the commercial payer.

FDA-approved indications and ICD-10 crosswalk for J0775

The FDA has approved Xiaflex for exactly two indications. Claims submitted with any other diagnosis code will be denied as non-covered or investigational. Coders should confirm the treating physician’s documented diagnosis maps to one of these two ICD-10-CM codes before submission.

Dupuytren’s contracture (M72.0) is the more commonly billed indication. Hand surgeons and orthopedic practices treating finger cord contractures use this code on the vast majority of J0775 claims. For urologists and men’s health providers treating Peyronie’s disease, N48.6 is the required companion code.

Practices specializing in these conditions can benefit from dedicated workflows in a plastic surgery practice software or a purpose-built men’s health clinic software platform that tracks diagnosis codes against drug administration records.

Off-label use of Xiaflex (for example, frozen shoulder or plantar fibromatosis) is not supported by J0775 under Medicare or most commercial plans. Document the indication precisely in the procedure note, including cord or plaque location, to support the diagnosis code on the claim.

Units of service and dose calculations for HCPCS code J0775

The most common billing error for J0775 is incorrect unit reporting. Each 0.01 mg of collagenase equals one billable unit. The number of units on the claim must match the dose administered, not the vial size.

A 0.58 mg dose drawn from a 0.9 mg vial leaves 0.32 mg (32 units) of residual drug. That waste must be accounted for using the JW or JZ modifier.

Bill 58 units administered under the primary claim line and 32 units of waste on a separate line with modifier JW. Billing 90 units without a JW line when only 58 mg was administered overstates the dose and triggers medical review.

JW and JZ modifier guidance for J0775

CMS updated its JW and JZ modifier policy in 2023 to make waste reporting mandatory for single-dose vials on all claims subject to the policy. J0775 falls within this requirement. Practices that skip the modifier risk both claim denials and post-payment audits.

• JW modifier (drug waste): Used when a portion of the vial is discarded after the administered dose is drawn. Bill the administered units on line 1 (no modifier) and the discarded units on line 2 with modifier JW. CMS reimburses the waste line at the same ASP-based rate, so there is a financial benefit to reporting it correctly.
• JZ modifier (no drug waste): Used when the entire vial contents are administered with zero waste. Applies when a 0.9 mg dose is given in a Peyronie’s protocol where the full vial is used. This modifier confirms to the payer that no waste occurred and no additional waste line is forthcoming.

Both modifiers are documented in the CMS JW/JZ Modifier Policy. Verify the current requirements with your MAC, as enforcement timelines and claims editing rules vary by jurisdiction. Robust patient data security tools that maintain immutable drug administration logs help practices respond quickly when auditors request supporting documentation for modifier claims.

Medicare reimbursement and fee schedule for J0775

Medicare Part B reimburses J0775 under the buy-and-bill model at 106% of the Average Sales Price (ASP). The ASP is recalculated quarterly by CMS based on manufacturer-reported sales data. The dollar rate per unit fluctuates each quarter, so practices must verify the current ASP rate before forecasting drug margins.

For a state workers’ compensation benchmark, Oregon’s Workers’ Compensation Division published a maximum payment of $99.83 per unit for J0775 effective April 1, 2025. This state-specific rate illustrates the wide variation possible between payer types. Medicare ASP rates, commercial contracted rates, and state workers’ comp schedules are all different figures. Never apply one payer’s rate to another payer’s claims.

In ambulatory surgery center (ASC) settings, J0775 is separately payable as an ancillary drug (per CMS’s quarterly ASC Addendum BB) when billed alongside an approved ASC surgical procedure on the same claim. ASC reimbursement is packaged differently from the physician office rate, so confirm ASC-specific drug payment rules with your MAC before billing collagenase injections in that setting.

Prior authorization requirements for HCPCS code J0775

Most commercial payers require prior authorization for Xiaflex before the first injection cycle. Authorization requirements vary significantly by plan, and failing to obtain approval before administering the drug typically means the practice absorbs the full drug cost. The framework below reflects documented policies from major payers as of 2026.

Always verify current authorization requirements directly with the patient’s plan before scheduling the injection. Payer policies change annually, and coverage criteria for Xiaflex can include step-edit requirements, like prior conservative treatment, that differ from one plan to the next.

Sound HIPAA compliance for medical offices means keeping a dated copy of the payer’s authorization confirmation in the patient record alongside the drug administration documentation.

Reduce J0775 claim errors with smarter practice workflows

Pabau helps hand surgery, orthopedic, and urology practices manage drug administration records, prior authorization tracking, and claim submission in one integrated platform. See how practices reduce billing errors and recover drug costs more reliably.

Book a demo

Related CPT codes billed with J0775

J0775 covers the drug only. The physician’s work of the injection procedure is billed separately using CPT codes. Coders must bill both the drug code and the procedure code on the same claim to capture full reimbursement. Review our medical billing guide for broader guidance on pairing drug and procedure codes correctly.

• CPT 20527 (Dupuytren’s): Injection, enzyme (eg, collagenase), palmar fascial cord. This is the physician work of administering the Xiaflex injection itself, billed alongside J0775 on the same encounter.
• CPT 26341 (Dupuytren’s): Manipulation, palmar fascial cord, post enzyme injection. Billed at the follow-up visit when the cord is manually ruptured.
• CPT 54200 (Peyronie’s): Injection procedure for Peyronie’s disease. Used by urologists billing the physician work component for plaque injections.
• Evaluation and management (E/M) codes: A separate E/M visit, such as CPT 99205 for a new patient, is payable on the same day when a significant, separately identifiable service is documented. Append modifier 25 to the E/M code if billing both the E/M and the injection procedure on the same date.

The National Correct Coding Initiative (NCCI) edits govern which CPT codes can be billed together with J0775. Before submitting, check for CCI column 1/column 2 pairs and Medically Unlikely Edits (MUEs) that may restrict units. Practices using automated billing workflows can build pre-submission edit checks directly into their claim scrubbing process.

Claim submission workflow and documentation requirements

A complete J0775 claim requires several documentation elements beyond the code itself. Missing any one of them is the fastest path to denial or a post-payment audit.

• Procedure note: Confirm palpable cord (M72.0) or palpable plaque (N48.6), injection site, dose administered, lot number, and NDC.
• Dose and units: State the exact milligrams administered. Calculate units (mg administered / 0.01) and document the calculation in the chart.
• Waste documentation: Record residual volume returned to vial or discarded. This is the source data for the JW modifier units on the claim.
• Prior authorization number: Include in Box 23 of the CMS-1500 claim form when the payer required pre-approval.
• NDC reporting: Many payers require the National Drug Code (NDC 66887-0003-xx) in the SV101 or equivalent claim field alongside J0775. This applies even to less common drug codes like J3490, so confirm your payer’s NDC reporting requirements before the first submission.

Standardizing intake and treatment documentation through digital forms reduces transcription errors between the clinical record and the billing system. When the administered dose and NDC are captured at the point of care and flow automatically into the billing workflow, unit errors and missing NDC fields become far less common.

Structured digital templates, like the ones covered in our guide to medical forms, cut down on the transcription errors behind many drug claim discrepancies.

Common denial reasons and how to appeal J0775 claims

Even well-documented claims for high-cost injectables like J0775 or J9312 get denied. Knowing the most common reasons helps billers respond quickly and prevent the same error from recurring.

Practices that implement structured time-saving features during charge capture significantly reduce first-pass denial rates on high-cost drug codes. When drug lot numbers, NDCs, and administered doses are locked into the clinical record at the moment of administration, billers spend far less time chasing documentation before deadlines.

HCPCS code J0775 lookup and verification resources

Before submitting any J0775 claim, verify the code against authoritative sources. Code descriptions, coverage policies, and fee schedules update annually (and ASP rates update quarterly). Rely on primary sources, not assumptions carried over from a prior year.

• CMS HCPCS overview: The official CMS reference for HCPCS Level II code structure, annual updates, and category definitions.
• AAPC Codify HCPCS lookup: Cross-references J0775 coverage notes, ASC classification flags, and payer-specific policy links.
• CMS fee schedule lookup: Current ASP-based reimbursement rates by HCPCS code and MAC locality.
• PGM Billing HCPCS lookup: Free HCPCS code search using CMS data, useful for quick descriptor confirmation.

Pabau’s prescription management software gives practices a centralized record of drug purchases, administered doses, and NDC data that feeds directly into billing documentation. For practices performing regular Xiaflex injection cycles, having this data structured and searchable reduces the administrative burden on both clinical and billing staff.

Conclusion

HCPCS code J0775 is a high-stakes billing code: The drug cost is significant, the documentation requirements are specific, and payer scrutiny on collagenase claims is consistent.

Getting unit calculations right, applying JW or JZ modifiers correctly, and securing prior authorization before the first injection are the three levers that most directly affect clean claim rates and cash flow for Dupuytren’s and Peyronie’s practices.

Pabau’s integrated practice management platform connects drug administration records to billing workflows so the data billers need is captured at the point of care, not reconstructed from memory after the fact. To see how practices use Pabau to reduce drug claim errors and shorten reimbursement cycles, book a demo.

Continue your research

Billing another high-cost HCPCS drug code? Our guide to HCPCS A9502 covers the same unit-conversion and modifier logic for radiopharmaceutical claims.

Managing other biologic injectables? HCPCS J1745 follows the same buy-and-bill and JW/JZ modifier rules as Xiaflex.

Tracking functional outcomes after a Dupuytren’s release? The Action Research Arm Test gives providers a standardized way to measure hand function before and after treatment.

Frequently Asked Questions